Novel treatments offer new hope for patients with autoimmune disease

Medical Xpress | March 04, 2019

Autoimmune diseases, including type 1 diabetes and multiple sclerosis, arise when the body's immune cells attack itself. Current treatments eliminate these misfunctioning immune cells, but also destroy normal, protective immune cells, leaving patients susceptible to immune deficiency and opportunistic infections. Researchers at the University of Utah Health have developed a new approach that targets the misfunctioning immune cells while leaving normal immune cells in place. The results of their study are available online in the March 4 issue of Nature Biomedical Engineering. "We are really taking treatment for the autoimmune disease in a new direction," begins Mingnan Chen, Ph.D., assistant professor in Pharmaceutical Chemistry at U of U Health. "This is the first time anyone has looked at the programmed cell death protein (PD-1) cells as a target to develop therapeutics for autoimmune disease." The team tested the treatment in a mouse model that mimics type 1 diabetes. They found the treatment delayed the onset of diabetes in mice (29 weeks old compared to 19 weeks old for control-treated mice). In addition, the treatment was also applied to a mouse multiple sclerosis model (experimental autoimmune encephalomyelitis). Not only did the treatment halt the progression of paralysis in the six mice in this model, but these mice also regained the ability to walk. The team monitored the mice for 25 days after treatment and found the paralysis did not return.

Spotlight

The Department of Biotechnology, Faculty of Engineering & Technology, SRM University constantly provides the latest developments in the fields of pharmaceutical, bio-pharmaceutical, and drug discovery sectors, healthcare, diagnostic and therapeutic, plant and animal sciences, and environmental sectors along with the core subjects.

Spotlight

The Department of Biotechnology, Faculty of Engineering & Technology, SRM University constantly provides the latest developments in the fields of pharmaceutical, bio-pharmaceutical, and drug discovery sectors, healthcare, diagnostic and therapeutic, plant and animal sciences, and environmental sectors along with the core subjects.

Related News

RESEARCH

TetraScience R&D Data Cloud Selected by Leading Clinical-Stage Biotechnology Company

TetraScience | September 03, 2021

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data science applications including AI/ML, it's important to start with harmonizing R&D data in the cloud," stated Chad Garrett, TetraScience CRO, "We're excited to partner with Zymeworks on their data cloud initiative and help them deliver on their mission to enable patients to return home to their loved ones, disease free." The initial Zymeworks deployment of Tetra Data Platform is in production and integrated with key systems and instruments supporting critical lab workflows. By automating and standardizing the flow of data across all sources and targets, the Tetra R&D Data Cloud will deliver faster and richer insights for Zymeworks' scientists. Additionally, Zymeworks will benefit from cloud-native architecture with greater uptime, security, redundancy, governance, and archival capabilities. About TetraScience TetraScience is the R&D Data Cloud company with a mission to transform life sciences R&D, accelerate discovery, and improve and extend human life. The Tetra R&D Data Cloud provides life sciences companies with the flexibility, scalability, and data-centric capabilities to enable easy access to centralized, harmonized, and actionable scientific data and is actively deployed across enterprise pharma and biotech organizations. As an open platform, TetraScience has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences R&D.

Read More

MEDTECH

Medtronic Expands Minimally Invasive Spine Surgery Ecosystem with Next-Generation Spinal Technologies

Medtronic plc | October 01, 2021

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ PL and PL40 feature a unique design for anterior rim engagement, a beveled tip for ease of insertion, seamless integration with StealthStation™ Navigation, simplified bone graft delivery, and active expansion at the precise angle and lift that surgeons need for minimally invasive, patient-specific solutions to meet sagittal alignment goals. The Space-D™ Access System, which enables pedicle-screw-based distraction, retraction and compression, compatible with Medtronic's leading MIS screw system, CD Horizon™ Solera™ Voyager™, enabling simpler, all-in-one access for surgeons, making procedures more efficient and reproducible. Accelerate™ Graft Delivery System with Grafton™ DBF enables more controlled and efficient delivery of graft material into the disc space or other locations. Accelerate enables placement of more bone graft2 to facilitate fusion and is nine-times faster than traditional graft delivery methods.3 Bone grafting is also more controlled and easier for surgeons to visualize. At Medtronic, we continue to raise the bar in minimally invasive spine surgery through our commitment to driving innovation and expanding our MIS capabilities, Our seamless integration of implants, instrumentation, and enabling technologies into a single ecosystem is helping surgeons remove variability in the surgical procedure, streamline and personalize care, and enable better patient outcomes. - Carlton Weatherby, vice president and general manager of Spine & Biologics within the Cranial & Spinal Technologies business Advancing Care with MIS+ TLIF More than 450,000 spinal fusion procedures4 are performed in the United States each year to reduce pain, improve stability, or correct deformities of the spine. About 200,000 are lower or lumbar fusion procedures,5 which treat conditions such as degenerative disc disease, herniated disc, fractured vertebrae, spinal stenosis, and other conditions. One of the most common spinal fusion procedures is transforaminal lumbar interbody fusion (TLIF). During a TLIF procedure, a disc is removed from the lumbar spine, and two vertebrae are joined together using screws or rods. An interbody fusion spacer is inserted into the space, and a bone graft or bone substitute is placed into the space. As the bone heals, it fuses the vertebrae together to form one bone. The new additions to Medtronic's MIS+ portfolio create the most complete MIS+ TLIF solution available for surgeons. A complete procedural solution allows surgeons to provide the benefits of minimally invasive spine care – including lower infection and complication rates,1 less blood loss,1 smaller incisions, reduced hospital stays,1 and less pain6 – to more patients. Compared to open TLIF, MIS+TLIF requires a smaller incision and less muscle and tissue disruption, which can mean a faster recovery time after the operation.7, 8, 9 Together, these technologies improve clinical and economic value while reducing OR time with a fully streamlined procedure1. About Medtronic Medtronic plc, headquartered in Dublin, Ireland, is among the world's largest medical technology, services, and solutions companies alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Read More

CELL AND GENE THERAPY

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

AgeX Therapeutics | November 24, 2021

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, and that it has stockholders equity of less than $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter, AgeX may provide the Exchange staff with a plan (the "Plan") by December 17, 2021 advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by June 17, 2023. AgeX intends to submit a Plan by the December 17, 2021 deadline. There is no assurance that the Exchange staff will accept the Plan. If the Exchange staff accepts the Plan, the Exchange staff will review AgeX’s compliance with the Plan on a quarterly basis and if AgeX does not show progress consistent with the Plan or is not in compliance with the Exchange’s continued listing standards by June 17, 2023, the Exchange will commence delisting procedures. If AgeX does not submit the Plan or if the Exchange staff does not accept the Plan, the Exchange staff will promptly initiate delisting proceedings. AgeX intends to make arrangements to have its common stock quoted on an electronic interdealer quotation system if its common stock is delisted from the Exchange. About AgeX Therapeutics AgeX Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeX’s PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem® is AgeX’s delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

Read More